Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amatuximab + Pemetrexed and Cisplatin in Unresectable Malignant Pleural Mesothelioma
NCT02357147Phase 2Terminated
- Sponsor
- Morphotek
- Start
- Nov 2015
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of amatuximab in malignant pleural mesothelioma (MPM), sponsored by Morphotek. Started Nov 2015; status: terminated.
02
Drugs
amatuximab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02357147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02357147.